» Articles » PMID: 23224852

Epidemiological Profile of Common Haemoglobinopathies in Arab Countries

Overview
Publisher Springer
Specialty Health Services
Date 2012 Dec 11
PMID 23224852
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Haemoglobinopathies including the thalassemias and sickle cell disease are known to be prevalent inherited disorders in most Arab countries with varying prevalence rates and molecular characterisation. β-thalassemia is encountered in polymorphic frequencies in almost all Arab countries with carrier rates of 1-11 % and a varying number of mutations. The most widespread mutation in Lebanon, Egypt, Syria, Jordan, Tunisia and Algeria is the IVS-I-110 (G>A). In the Eastern Arabian Peninsula, the Asian Indian mutations (IVS-I-5 (G>C), codons 8/9 (+G) and IVS-I (-25 bp del)) are more common. The α-thalassemias are encountered in the majority of Arab countries in frequencies ranging from 1 to 58 % with the highest frequencies reported from Gulf countries. The (-α(3.7)) mutation is the most frequent followed by the non-deletional α2 polyadenylation signal mutation (AATAAA>AATAAG) and the α2 IVS1 5-bp deletion. The rates of sickle cell trait in Arab countries range from 0.3 to 30 %, with the Benin, the Arab-Indian and the Bantu haplotypes constituting the bulk of the haplotypes, leading to two major phenotypes; a mild one associated with the Arab-Indian and a severe one with the Benin and Bantu haplotypes. Public health approaches targeting prevention of haemoglobinopathies in Arab countries include newborn screening for sickle cell disease, and premarital screening for carriers of β-thalassemia and sickle cell disease. These services are still patchy and inadequate in many Arab countries recommending the upgrade of these services with strengthening of the education and training of health care providers and raising public awareness on the feasibility of prevention and care for haemoglobinopathies.

Citing Articles

Evaluating the Mentzer Index for Screening of Iron Deficiency Anemia and Beta Thalassemia Among Infants Visiting Primary Health Centers in Dubai, United Arab Emirates: A Retrospective Study.

Alkamali A, Alshafiei L, AlJasmi M, Helali H, Alhmid I, AlOlama F Cureus. 2024; 16(8):e66286.

PMID: 39238747 PMC: 11375987. DOI: 10.7759/cureus.66286.


A Systematic Review of the Gene-Lifestyle Interactions on Metabolic Disease-Related Outcomes in Arab Populations.

AlAnazi M, Flores Ventura E, Lovegrove J, Vimaleswaran K Nutrients. 2024; 16(15).

PMID: 39125399 PMC: 11314532. DOI: 10.3390/nu16152519.


Case Report: β-thalassemia major on the East African coast.

Macharia A, Mochamah G, Makale J, Howard T, Mturi N, Olupot-Olupot P Wellcome Open Res. 2023; 7:188.

PMID: 37811313 PMC: 10551670. DOI: 10.12688/wellcomeopenres.17907.1.


Prevalence and Management of Transfusional Iron Overload in Syrian Beta Thalassemia Major Patients Pre and during the Syrian Conflict.

Touma H, Youssef L, Al-Salhi L, Ismail Al-Khalil W, AlKeba K Biomed Res Int. 2023; 2023:8911518.

PMID: 37743972 PMC: 10513871. DOI: 10.1155/2023/8911518.


Evaluation of the validity of the pre-marriage mean corpuscular volume value as a predictive test for b-thalassemia carrier status.

Almomani A, Shraim A, Atoom A, Abdel M, Alhmoud J J Med Biochem. 2023; 42(2):195-205.

PMID: 36987417 PMC: 10040200. DOI: 10.5937/jomb0-37682.


References
1.
El-Beshlawy A, Kaddah N, Moustafa A, Mouktar G, Youssry I . Screening for beta-thalassaemia carriers in Egypt: significance of the osmotic fragility test. East Mediterr Health J. 2007; 13(4):780-6. View

2.
Charafeddine K, Ismaeel H, Charafeddine M, Inati A, Koussa S, Naja M . Survival and complications of beta-thalassemia in Lebanon: a decade's experience of centralized care. Acta Haematol. 2008; 120(2):112-6. DOI: 10.1159/000171088. View

3.
Labie D, Bennani C, Beldjord C . Beta-thalassemia in Algeria. Ann N Y Acad Sci. 1990; 612:43-54. DOI: 10.1111/j.1749-6632.1990.tb24289.x. View

4.
Talafih K, Hunaiti A, Gharaibeh N, Gharaibeh M, Jaradat S . The prevalence of hemoglobin S and glucose-6-phosphate dehydrogenase deficiency in Jordanian newborn. J Obstet Gynaecol Res. 1996; 22(5):417-20. DOI: 10.1111/j.1447-0756.1996.tb01050.x. View

5.
Alhamdan N, Almazrou Y, Alswaidi F, Choudhry A . Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genet Med. 2007; 9(6):372-7. DOI: 10.1097/gim.0b013e318065a9e8. View